A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Cancer
Sponsor: Arcus Biosciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT6666
U.S. Govt. ID: NCT04772989
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to help the Sponsor understand whether study drugs, AB308 together with zimberelimab (also called AB122) can be safely given to patients with advanced cancers. Zimberelimab (AB122) is an investigational drug that has been shown in animal studies to slow or stop the growth of some cancers by using the immune system. AB308 is an investigational drug that targets and directly blocks a molecule on T cells or Natural Killer (NK) cells (another type of white blood cell produced by your body) called TIGIT (TIGIT stands for T-cell immunoreceptor with immunoglobulin and ITIM domains) to allow for re-activation of the body's natural immune response to foreign cancer cells. This is the first study in which AB308 is being given to humans. Cancers include: Bladder cancer, breast cancer, esophageal cancer, ovarian cancer, lung cancer, lymphoma, melanoma, pancreatic cancer, and prostate cancer.
Investigator
Benjamin Izar, MD
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with advanced cancer for which there is no treatment currently available? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162